-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 FvKx3TxrmOWAjZFY2gBPQRU5hg/YUopZrYRf+Vi0CdCGiK81gvMhlQp47StXnVrn
 Dulk0lLxCsv4+CxgGyMNBQ==

<SEC-DOCUMENT>0000950123-10-030950.txt : 20100331
<SEC-HEADER>0000950123-10-030950.hdr.sgml : 20100331
<ACCEPTANCE-DATETIME>20100331170155
ACCESSION NUMBER:		0000950123-10-030950
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100330
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100331
DATE AS OF CHANGE:		20100331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		10720124

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c98649e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): March 30, 2010</B>


<P style="font-size: 24pt" align="center"><B>GEOVAX LABS, INC.<BR>
</B><FONT
style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>000-52091</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>87-0455038</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>1900 Lake Park Drive, Suite
380<BR>
Smyrna, Georgia<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>30080</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(678) 384-7220</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>



<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt; text-indent: 4%" align="left">This Form 8-K and
other reports filed by GeoVax Labs, Inc. (the &#8220;registrant&#8221;) from
time to time with the Securities and Exchange Commission (collectively the
&#8220;Filings&#8221;) contain forward looking statements and information that
are based upon beliefs of, and information currently available to, the
registrant&#8217;s management as well as estimates and assumptions made by the
registrant&#8217;s management. When used in the Filings the words
&#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;,
&#8220;expect&#8221;, &#8220;future&#8221;, &#8220;intend&#8221;,
&#8220;plan&#8221; or the negative if these terms and similar expressions as
they relate to the registrant or the registrant&#8217;s management identify
forward looking statements. Such statements reflect the current view of the
registrant with respect to future events and are subject to risks,
uncertainties, assumptions and other factors relating to the registrant&#8217;s
industry, operations and results of operations and any businesses that may be
acquired by the registrant. Should one or more of these risks or uncertainties
materialize, or should the underlying assumptions prove incorrect, actual
results may differ significantly from those anticipated, believed, estimated,
expected, intended or planned.

<P style="font-size: 10pt" align="left"><B>Item&nbsp;8.01 Other Events</B>

<P style="font-size: 10pt; text-indent: 7%" align="left">On March&nbsp;30, 2010
we issued a press release announcing that we are now allowed by the U.S Food
and Drug Administration to begin a Phase 1 clinical trial for our therapeutic
vaccine, which is intended as treatment for individuals infected with HIV
(Human Immunodeficiency Virus). A copy of the press release is attached to this
Current Report as Exhibit&nbsp;99.1.

<P style="font-size: 10pt" align="left"><B>Item&nbsp;9.01 Financial Statements
and Exhibits</B>

<P style="font-size: 10pt; text-indent: 7%" align="left">Exhibit&nbsp;99.1
Press Release

<P style="font-size: 10pt" align="left"><B>SIGNATURES</B>

<P style="font-size: 10pt; text-indent: 7%" align="left">Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report to be signed on its behalf by the undersigned
hereunto duly authorized.

<P style="font-size: 10pt" align="left">Dated: March&nbsp;31, 2010

<P style="font-size: 10pt; margin-left: 46%" align="left">GEOVAX LABS, INC.

<P style="font-size: 10pt; margin-left: 46%" align="left">By:<U> /s/ Mark W.
Reynolds&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><br>
Mark W. Reynolds
<BR>
Chief Financial Officer

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c98649exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><IMG src="c98649p9864901.gif" alt="(GEOVAX LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 50%"><B>Contact</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 50%">At the Company:<BR>
Robert McNally, President &#038; CEO<BR>
(678)&nbsp;384-7220 or <u>rmcnally@geovax.com</u>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 50%">At The Investor Relations Group:<BR>
Investor Relations<BR>
James Carbonara / Jason Strominger<BR>
or<BR>
Public Relations<BR>
Janet Vasquez / Robin O&#146;Malley<BR>
(212)&nbsp;825-3210

</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>FOR IMMEDIATE RELEASE</B><BR><B>
MONDAY, MARCH 30, 2010</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GEOVAX LABS GRANTED ALLOWANCE BY FDA TO START PHASE 1<BR>
CLINICAL TRIAL FOR HIV/AIDS THERAPEUTIC VACCINE</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B><I>Company Will Begin Non-Blinded Study in HIV Infected Individuals<BR>
Who Started Drug Treatment During Their First Year of Infection</I></B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>SMYRNA, GA &#151; March&nbsp;30, 2010 &#151; </B>GeoVax Labs, Inc. (OTCBB: GOVX), a biotechnology company that
creates, develops, and tests innovative HIV/AIDS vaccines, is now allowed by the FDA (US Food and
Drug Administration) to begin a phase 1 clinical trial for GeoVax&#146;s therapeutic vaccine, which is
intended as a treatment for individuals infected with HIV (Human Immunodeficiency Virus). The
company will begin a non-blinded study in HIV infected individuals who started drug treatment
during their first year of infection.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Robert McNally, Ph.D., President and CEO of GeoVax, stated, &#147;Based upon preclinical animal data, we
believe our therapeutic vaccine may improve treatment options for people infected with HIV and are
delighted we will be able to begin a phase 1 clinical trial. An unmet need exists in the market for
a HIV therapeutic vaccine if it can reduce the need for expensive and poorly tolerated lifelong
oral medications currently available to infected individuals. We also recognize that this trial
will enable GeoVax to gather crucial information toward our vaccine&#146;s success on a more timely
basis than the time required to perform a preventative trial. &#148;
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The protocol for the Phase 1 clinical trial, conceived in collaboration with ARCA (AIDS Research
Consortium of Atlanta), will carefully monitor safety while evaluating the ability of the vaccine
to elicit protective immune responses in vaccinated participants. The next step of starting the
process will be a submission by ARCA to the IRB (Institutional Review Board) for local review of
trial documentation, a standard requirement to protect human subjects. The trial is based on the
achievement of post-vaccine viral control in animal studies conducted in recently infected
non-human primates at the Yerkes National Primate Research Center, affiliated with Emory
University.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt">MORE
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About GeoVax Labs, Inc.</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV-1 (Human
Immunodeficiency Virus &#151; AIDS) and other infectious agents. Our goals include developing AIDS
vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA
guidelines), conducting human trials for vaccine safety and effectiveness, and obtaining regulatory
approvals to move the product forward. All preventative phase 1 human clinical trials conducted to
date tested various combinations and doses of our DNA and MVA AIDS vaccines in human volunteers for
their demonstrated ability to raise anti-HIV immune responses as well as for their safety.
Successful results from all phase 1 testing supported the initiation of the first phase 2 testing.
GeoVax&#146;s phase 2 human trial began in January&nbsp;2009 and will involve 225 participants at sites in
the United States and South America. Long term, we expect that GeoVax will grant manufacturing and
distribution rights in several global markets in return for upfront fees, collaborative development
agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and
distribution will also be considered by GeoVax. For more information, please visit <u>www.geovax.com</u>.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Forward-Looking Statements</B><BR>
<I>Certain statements in this document are &#147;forward-looking statements&#148; within the meaning of the
Private Securities Litigation Reform Act. These statements are based on management&#146;s current
expectations and are subject to uncertainty and changes in circumstances. Actual results may
differ materially from those included in these statements due to a variety of factors, including
whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a
timely manner, GeoVax&#146;s vaccines will be safe for human use, GeoVax&#146;s vaccines will effectively
prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and
marketed, GeoVax raises required capital to complete vaccine development, there is development of
competitive products that may be more effective or easier to use than GeoVax&#146;s products, GeoVax
will be able to enter into favorable manufacturing and distribution agreements, and other factors,
over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking
statements, and does not intend to do so. More information about these factors is contained in
GeoVax&#146;s filings with the Securities and Exchange Commission including those set forth at &#147;Risk
Factors&#148; in GeoVax&#146;s </I><I>Form 10-K</I><I>.</I>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt">###
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c98649p9864901.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c98649p9864901.gif
M1TE&.#EAT@!*`/<```!2E`!2G`!:E`!:G`!:I0!CI0!CK0A:G`ACG!!CG!!C
MI1ACG!ACI1AKI2%KI2%SI2ESI2ESK3%SK3%[K3E[K3E[M3F$K3F$M4*$K4*$
MM4J$M4J,M5*,M5*,O5*4O5J4O6.4O6.<O6.<QFN<QFNEQG.EQGNEQGNESGNM
MSH2MSH2USHRUSHRUUI2UUI2]UIR]UIS&UJ6]UJ7&UJ7&WJW&WJW.WK7.WK7.
MY[76Y[W.Y[W6Y\;6Y\;>Y\;>[\[>Y\[>[];>[];G[][G[][G]][O]^?O]^_O
M]^_W]^_W__?W__?______P``````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"'Y!```````+`````#2`$H`AP!2E`!2G`!:E`!:
MG`!:I0!CI0!CK0A:G`ACG!!CG!!CI1ACG!ACI1AKI2%KI2%SI2ESI2ESK3%S
MK3%[K3E[K3E[M3F$K3F$M4*$K4*$M4J$M4J,M5*,M5*,O5*4O5J4O6.4O6.<
MO6.<QFN<QFNEQG.EQGNEQGNESGNMSH2MSH2USHRUSHRUUI2UUI2]UIR]UIS&
MUJ6]UJ7&UJ7&WJW&WJW.WK7.WK7.Y[76Y[W.Y[W6Y\;6Y\;>Y\;>[\[>Y\[>
M[];>[];G[][G[][G]][O]^?O]^_O]^_W]^_W__?W__?______P``````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````C^`)<('$BP
MH,&#"!,J7,BPH<.'$"-*G$BQHL6+&#-J%+CB```!`SX$V4BRI,F3*#/J$!``
M)(B4,&/*G%D2Q("/#(C0W,FSI\^!11!\'&#BI]&C"8T<*1+$AXX:,EZP2(&B
M!(D0(#YTX+!!@X8,&"B`%8M!PX8-'#B``"&B1(D4*5J\F%%#AX\@18X86;CB
MIH`#(Y$*EHE$"`\;+U:4",$APP0'"Q`<$`!@@&7+!`A@OLRYLV?.FC5?_OCW
MP`('$S!T"&%BQ0L;/(H8@7!S`(?!N#,F*<*#AN(/&2`LF'PY-.?*'UM2]EN9
M)4CGGZ,/>#Z].G3/HBN[T/'QXXT@.V3^YQZ_L,B.&2E"8'"0`.0`T:-9=J=\
M'71G`$/_)MC?X/2"!_X!"%E_^QTPF4?X26?=``<4P4%M$"1!6P(.8`!""C.$
MIP1Y@AG!PPLE<!!!>YM9YAQ^].77&7T)+``!!1M\,(()*LA%@PTZ\`!$$$04
M(=L12!BA1!)"$CDDD$L508000?S`0PXUS"!5"HMUH,%CP[$4@A"3:6>#>RLF
M(`$');P0&X<R%:$#"R%0D$")T[6$WWR5W2>``Q)L$`(*+="@`Q!Y;8B;$D80
MX<,-1YC@5P)%=#!``)S59QD`"U`@P@HZ[(4F1DH`\<((;H*478HH-O?>HP)0
MR,$(*V0XQ!'^FRZ41`/+O22$#C*D($(&#A`7:9@4E!!#$$G$^M`/+X``@:B3
MIIAB=9,F,`$'&,8FJ+$.R>#7`#P<I(2:+Z#`@00)U&DBI)<)``$(+P"!K4%%
MT!""!,Q.1R=]Z$ZG``8CO!#>NQ514!L%#ZGIP@@8,`!F;9<=`,$(-!1A;!`N
M;/#FJ-V5RIG#(+2P`ZP`7^1#BC)0=,0.+LR[\,()<.""$.,-T4(&!YQZ[WRC
M23""#(&%K)$(M3F`1$9#T%`"!2Q9UE+#&KQ\E!$T6!P?G<F9R,`'+O3L\T9&
MM%=94241,4,(#H!I[@$<T*`I34&<\,#4S@YUT\,V@,R0$4'H8$/^#3CF@*,.
M@.^@=9HQS"!#AA3U]1%@*2FQ0PI(*PVF`R@,?A(/']3<K)S/6N9`"#H4VU`1
M+W30ZW+.!0"`G`,H$,-.2J20;@H315#;;3,%`;E[<A\`0K>7=\![W)35B38-
M0SM$1`D+C,;<?`+0-P"C/(U06X,1<4>?#3W]4$+9]IKX`?`:!1&"YC<7;UD#
M)EB^T`L--$N=@M&[G](1"E>V0D0/5@:!44B800;J9+P02`PC+H@?<YXG-PBP
MX(`/48)-;E*GEC3``1#(8`8A`YD'>,1^*2D!A-;&$"XM9W](T<$'0+*T`33@
M!19IU.:(9YD%K,!N#TG"!NP%D@-\@&?^21B2$)-@)"(%@0,_Z(D)*U.#AZ!@
M41!$2@\X`!*Y=2"*#_$!;3AWL^F,`(L/>=!R`!`"$!YD*3[Y0&TTX)`D.*`V
M(2"/#@3&N@CX('L*8`[Q*A,!'51$=@E2``U\MI+%)9$A-*"/``Y)GA4@8%L*
M@`@/FH<<XD$*!#B,R`^J.(`%D"]D`JO,"!JB@8'%Z@<2V-8H&_*"5-Y+3MVA
MG45VN#@_;FT)+YB.`!:028-L<B@EB]41'#44&##D")2,&\Y06)$=2`\%MQ1(
M$B@Y@!8LQ'J568#H8J6$_G4R>0EQ`0'VJ+XX7B0$02,A24Y6@QL%X5H.`8(-
M:%"#'Z@S!<O^F8!"C$!-:!*$"#5HP0I<8(,#OJ`U+X`5Z4R0`A6DP`7J+`@/
M5@`7N.P@AQ:X"0&8B9!0GDB/`Y#`-BDRS>K(LB0XX`"M)N6P$KAK(4$H002&
M]X`0W%$@1.B2`'(03OH<`&8"L8'%\C4]#MS`F9J9@)!^P(',6&8"O10(#6I&
M@`((X`7@;(@0RC4`@BF$G/-IXD5XT!W&D40('2!@],R%`!.,M"`I>%.S'G69
M$&C*)I7Q0$)":1N!."A=G#/1"+P9S"7@LTX=.$@0WI1-1D)$4959"%@KXX"(
M2B27E9%`27CP1H:=:E*6R0`8D_"@;7UV.0.8@$Z<N3B@%J20WEG^0A`<,$YS
M?=9<0^$H-D%RTH%@P"\'L*5$AN"7A>0/7\4#R0<R@H+EX.X@-1`!"$)`W>I6
M%P0C$*M`@I#,Z61@!"7X``0J.8`,O)66R%G78B1`7@G`*@.U`5M!U.B_)13A
MC:C3``I28`(+5+([`X#A0)3@T0%P;R"`K$QO)3(=!BPD!`1(7V5*D!$1@L2<
M!M'6J8S#X7':4@FT6<X''*L$&Q28P@C>5@1J,-(Y;FNY-!B*`S))A'*!9'\[
M7$X''+N$'?QV/@'@Z!*(0,T&`%4'V]K`142YD$WJ$6>KO`@V!T`"A,"7-*11
M)(!?LH06,$?(`TD"??\2F"66-ZI+0&?^=_Q8MLH45B"`3%42OI0@^19$"6/6
MCD%NP$F"'0&_G01C1"S#XX/TSY(68.[M.KKA1H\J)$N836VB["UZ?4T@(O0?
MF@62@>4H67%=)8B$X+@$^(+DN=X*964$#%=5BK$RPJ5($0R`ZH04(<ZL,R1&
M,!O22D^@!"8P`;"%'6P3+*LRR]7>`&:\$!J8$L3*&:1"?C"9`"!`-E[CUD!J
M,)\==>FG"RGDC1%RZ$E=6LH/V+1!U'RO`7#9(JS]BVO#K`)U/Q'92U!!;5"L
M$"50,@%&,.&R&]+ICPQ2S>X>B#<QL(09#$7)#*&-GL]HN^2`)`,8J4$`YMT0
MZ]%0NQ1!0O/^QFV0MQI$4<I=PFZE39"8?B`$'\B*C0%32$@S!+(#V-\O4R4Q
M(*PU`(,$Y``6C!"\"L":"/G!`I+K`$%#Q`8VG$A'*"B]!10Z(G@=0(0D<F\!
M+-<FE(GUD&G[61XVR`8)HG1"0"W+4HX[TUK?D-#!?!"XNT`AY<:X168P`99+
M9`<3,/=R''!3BFA/?Q+!^7+5+`"0+\$%"QSC=(J`]I0SY-XYEVJ"('#?VJ!0
MWPIN2-99;9`9V&LH=H9($M+#<8DDP01R19$+#TR1*P\``5=7R`FJLURAI[XO
MTEEN$)SS/X:X'0!B!?$:Z;.``R:R,FQDR$P1?Y"MUD9Z?G>([AS^;Y$@9,Y$
MS2'Z0W80/@>T7B&*7P*=ESW2%03@`R@PP0GD+_\7;$@);3;P0H#P[9XIKHH7
M-A!!T"4(8$;J)SUW9Q`$MBC4E``&*&H\@"@F@3GNX1X6<%$3`5D@X0`8V!"[
MAV]NM!S\M@0#Q1!P-P$F1Q"T5%X$401>HSZ.54K0IQ!),`&L0WH#D6DL,0/B
MEEJ6=49.IQ$_,`+-PQEE)!%*<'P,@@(_6!`H9W/_=W0#\5(PU24#L`%HQF[Z
M1Q"[-8,$P6=U,@+P-!!'\&HL`68V$#[F]'\VAQ!$PA-%T`(44"<$D``FH!,0
M<0058%H.4`(?HQ"8MUQ+,&IU\@&%UQ#^&AA2+$80.G!E(`%Q!+%)R<5]:K0<
M&1!K25`#K@1@"3@01`8AVS1FF6<006`#/I!5.\$#)3!>594`(Y!["%&&J%(G
M`M``,,(5N(@6')!_@K@$/\!8[D$!(3`"U$6,PUB,KR--5U8G$/!R(#`!S>$_
M@B:#6G<0DC84`#`!+R=><Y4@G2@0,O@7CH4$$@<2,U`L)^,"*4`#>'@428`#
M(S!>!B``&T`#*8@0*A![J%4BHJ$9"=*+2Z`#;X):H5&0[R$:_&8$IB8WHP(I
M$6`_,0822&<01)!*VV(<V"@]I(=YU42*";`TJ8)!(#`#ZN83CH,"<]A))-"!
M^[="<"-A%U?^$$&0`>@"DT.!`':C!"6`/A8W*1\0A,JW`.UH$$<@`K2(,TLX
M9?SF?LZ%$(DT*1.0`@\H&$/P`A\P''1SCRT'.5RE()<1`"XPAC6@`5WIE9@4
MB60S/`OP`6)W$"M``&IW$#OP`0I3DPWP._9%&PPB`S=06I8!`9O&`AE@`CTP
M$6/($TKP`ROP`10@C#%P?@6A)E+R`I19F999F3(@:&H2%9?9F2]@.4G``U*2
M(4.I$$B0F0YQ,J/)`SA4!),Y%ZY!F3,0A!>!&#H`0ZF'F$'P`B<0`B70`CH@
M!(<93<3)$"[0`C7``;.5&[Q1`S%`3S]`!$U8G-2I?C3`4"606&C^XB-",`2E
M69W@>0,PD`,_8`.T!Y[HF9[JN9[LV9[N^9[P&9_R.9_T69_V>9\-H00X9`1[
MH9^$@D-'`#)!,`2B1D(!*A!'8"2D^`-361%)4)+XB1'D")@"`3_[HP$<2`$1
M`#(RT`"CA$PG!0,-X%X"P5F]UP`)8!J&*!`_(#!_85<G400+$'T1BA*;%`$#
MT0$$,`-&L$M%,%X$.AL!<$<O(`"!400,,!V'])9Q)#`P0EM-]V<"8`(M``$&
M('X8<00IP'TUNA&Y%&7+<BL!H&0:``!W!'GF1`$T.@("4*8S(!`V<8[[`2M&
M$'@S(`0"H$_VU0',-(1^9`2ML03)20'^(&!+F$,!(W!3-M`8)2`Q.E`Y0E`"
M8\,!3+@$6IH!:2,0.P`"%/`!+-FE"&$]$X`5*^0`)$@4:38`-X!_"``SPR=@
M/@``')"&M`-B`!`$9,5P<#9T1O!&&;`"@U,#!%!E;\D"SA8L+3)G!Y``&Q``
M#?("`>``I?0`8C8`BCE.%%`S]H@T&T`O-2`$"``!*-`>M`FJ'E4GMZ%&@Z0H
M-"`#!``VL`<R-.,C`+!<17``INIE429"=P<$9:H9_B000$!&L_(_/L`"0G`$
MG18$$E"`2R`#'5`#"4"A*\`!0D`NI!5@2R!"-9!+C9J&'%`#7?4#/D"2H)H4
MRRH$>6$]*K#^!&4#,Y!G;$*Y!/C'9=J2`")`103S)4J&3F]*L^,E.+!"!"U0
M+CUS!#XD.TTT`^,R7A3P`[)*$&EX`BW8ID<``0ZV!!]PJSO4'PYPEQ($$D][
ML@FQ$GJW!`^2`P-HJH(*`&\B2]SQIV4#&<V3`(9%`-!$+R-1!&JD`3E5?$L@
M,(4'8NS!<&DH$CD@`(F:<$O``G(Q`"UK!"AP(P-P`D4@`+<Q3=3J)@F;`RO@
M%("R`GE*M@CQEBB&!.UQ!,ZF5[X(``20;G!:?"5``"4`*T=``4/Z(`45/1(`
M`0=``!"@$Q10`(/Y(!0`3Z4T`!?UEB1@8@&6!/NQ`B!0`"40!`"8X``NH`$$
M\`*R8YX#`$U!$`"WH2@D\`)?.UL+@`,S,*:D>Q`H$`$'QK#+Y0(1(&!%0`%]
MYU<)L#\5:5X#@0(04`,=0`$G(P$2@$$:\`*B4P0@(`#C-`*9E`(1@&)'L`$`
M$`'BY4>`-STH1`-OU`"#5`(30#H1<%$Z``$PE`0D4!D4<$<],(<'8$#M.\,T
- -7,,V?,,XG,/Q&1``.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
